Siraj A. Misbah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Siraj A. Misbah has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
A. Aslam
From the Department of Clinical Immunology, Oxford Radcliffe Hospitals NHS Trust, Oxford, UK
1 shared publicationAamir Aslam
1 shared publicationAndreas Baumann
Department of Neurology, University Hospital Berne, Berne, Switzerland
1 shared publicationB. Grimbacher
Royal Free Hospital and University College London, London, UK
1 shared publicationB. Shine
Departments of Clinical Immunology and Clinical Biochemistry, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, U.K.
1 shared publicationChristine Costello
1 shared publication
Latest Publications
- 15 July 2011
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 166 (1) , 16-25
Bringing immunoglobulin knowledge up to date: how should we treat today?
Summary: Immunoglobulin (Ig) therapy is constantly evolving. Advances in the basic and clinical science of immunoglobulins have provided new perspectives in using polyclonal IgG to treat patients with primary immunodeficiencies. Recent meta-analyses of patient data and outcomes, optimization of IgG administration and better understanding of the IgG receptor variability and clinical effect are new concepts which practising immunologists can use in tailoring their approach to treating patients with primary immunodeficiencies. This manuscript presents the proceedings of a satellite symposium, held in conjunction with the European Society for Immunodeficiencies (ESID) 2010 meeting, to inform attendees about new scientific concepts in IgG therapy, with the goal of empowering expert level evaluation of what optimal IgG therapy is today.
- 15 July 2011
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 166 (1) , 16-25
Bringing immunoglobulin knowledge up to date: how should we treat today?
Summary: Immunoglobulin (Ig) therapy is constantly evolving. Advances in the basic and clinical science of immunoglobulins have provided new perspectives in using polyclonal IgG to treat patients with primary immunodeficiencies. Recent meta-analyses of patient data and outcomes, optimization of IgG administration and better understanding of the IgG receptor variability and clinical effect are new concepts which practising immunologists can use in tailoring their approach to treating patients with primary immunodeficiencies. This manuscript presents the proceedings of a satellite symposium, held in conjunction with the European Society for Immunodeficiencies (ESID) 2010 meeting, to inform attendees about new scientific concepts in IgG therapy, with the goal of empowering expert level evaluation of what optimal IgG therapy is today.
- 21 June 2011
- Published by Wiley in Journal of the Peripheral Nervous System
- Vol. 16 (2) , 92-97
A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open‐label proof‐of‐concept study
Intravenous immunoglobulin (IVIG) is the first‐line therapy for multifocal motor neuropathy (MMN). This open‐label multi‐centre study (NCT00701662) assessed the efficacy, safety, and convenience of subcutaneous immunoglobulin (SCIG) in patients with MMN over 6 months, as an alternative to IVIG. Eight MMN patients (42–66 years), on stable IVIG dosing, received weekly SCIG at doses equivalent to previous IVIG using a “smooth transition protocol”. Primary efficacy endpoint was the change from baseline to week 24 in muscle strength. Disability, motor function, and health‐related quality of life (HRQL) endpoints were also assessed. One patient deteriorated despite dose increase and was withdrawn. Muscle strength, disability, motor function, and health status were unchanged in all seven study completers who rated home treatment as extremely good. Four experienced 18 adverse events, of which only two were moderate. This study suggests that MMN patients with stable clinical course on regular IVIG can be switched to SCIG at the same monthly dose without deterioration and with a sustained overall improvement in HRQL.
- 21 June 2011
- Published by Wiley in Journal of the Peripheral Nervous System
- Vol. 16 (2) , 92-97
A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open‐label proof‐of‐concept study
Intravenous immunoglobulin (IVIG) is the first‐line therapy for multifocal motor neuropathy (MMN). This open‐label multi‐centre study (NCT00701662) assessed the efficacy, safety, and convenience of subcutaneous immunoglobulin (SCIG) in patients with MMN over 6 months, as an alternative to IVIG. Eight MMN patients (42–66 years), on stable IVIG dosing, received weekly SCIG at doses equivalent to previous IVIG using a “smooth transition protocol”. Primary efficacy endpoint was the change from baseline to week 24 in muscle strength. Disability, motor function, and health‐related quality of life (HRQL) endpoints were also assessed. One patient deteriorated despite dose increase and was withdrawn. Muscle strength, disability, motor function, and health status were unchanged in all seven study completers who rated home treatment as extremely good. Four experienced 18 adverse events, of which only two were moderate. This study suggests that MMN patients with stable clinical course on regular IVIG can be switched to SCIG at the same monthly dose without deterioration and with a sustained overall improvement in HRQL.
- Open Access
- 30 October 2009
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 158 (Supplement) , 51-59
Subcutaneous immunoglobulin: opportunities and outlook
Summary: Immunoglobulin (Ig) administration via the subcutaneous (s.c.) route has become increasingly popular in recent years. The method does not require venous access, is associated with few systemic side effects and has been reported to improve patients' quality of life. One current limitation to its use is the large volumes which need to be administered. Due to the inability of tissue to accept such large volumes, frequent administration at multiple sites is necessary. Most studies conducted to date have investigated the use of subcutaneous immunoglobulin (SCIg) in patients treated previously with the intravenous (i.v.) formulation. New data now support the use of s.c. administration in previously untreated patients with primary immunodeficiencies. SCIg treatment may further be beneficial in the treatment of autoimmune neurological conditions, such as multi-focal motor neuropathy; however, controlled trials directly comparing the s.c. and i.v. routes are still to be performed for this indication. New developments may further improve and facilitate the s.c. administration route. For example, hyaluronidase-facilitated administration increases the bioavailability of SCIg, and may allow for the administration of larger volumes at a single site. Alternatively, more concentrated formulations may reduce the volume required for administration, and a rapid-push technique may allow for shorter administration times. As these developments translate into clinical practice, more physicians and patients may choose the s.c. administration route in the future.
- 30 October 2009
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 158 (Supplement) , 51-59
Open AccessSubcutaneous immunoglobulin: opportunities and outlook
Summary: Immunoglobulin (Ig) administration via the subcutaneous (s.c.) route has become increasingly popular in recent years. The method does not require venous access, is associated with few systemic side effects and has been reported to improve patients' quality of life. One current limitation to its use is the large volumes which need to be administered. Due to the inability of tissue to accept such large volumes, frequent administration at multiple sites is necessary. Most studies conducted to date have investigated the use of subcutaneous immunoglobulin (SCIg) in patients treated previously with the intravenous (i.v.) formulation. New data now support the use of s.c. administration in previously untreated patients with primary immunodeficiencies. SCIg treatment may further be beneficial in the treatment of autoimmune neurological conditions, such as multi-focal motor neuropathy; however, controlled trials directly comparing the s.c. and i.v. routes are still to be performed for this indication. New developments may further improve and facilitate the s.c. administration route. For example, hyaluronidase-facilitated administration increases the bioavailability of SCIg, and may allow for the administration of larger volumes at a single site. Alternatively, more concentrated formulations may reduce the volume required for administration, and a rapid-push technique may allow for shorter administration times. As these developments translate into clinical practice, more physicians and patients may choose the s.c. administration route in the future.
- 1 May 2009
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 160 (5) , 1098-1102
An ‘n-of-1’ placebo-controlled crossover trial of intravenous immunoglobulin as adjuvant therapy in refractory pemphigus vulgaris
Pemphigus vulgaris (PV) is an organ-specific autoimmune blistering mucocutaneous disorder that is potentially fatal. High-dose intravenous immunoglobulin (IVIg) is increasingly used in the treatment of autoimmune diseases and it has been reported that it may also be effective in PV. To evaluate prospectively the efficacy of IVIg for PV using an 'n-of-1' placebo-controlled trial. A randomized, placebo-controlled, crossover trial of IVIg was conducted in a single patient with severe PV, comprising two phases of six consecutive months of either IVIg or placebo infusion. Before the commencement of the trial, the patient had received 18 months of IVIg but concerns about the continuing therapeutic efficacy of IVIg led to the double-blind placebo-controlled 'n-of-1' trial of IVIg. Pemphigus autoantibody titres were significantly higher when on placebo compared with IVIg treatment (median 1 : 80 vs. 1 : 20, P = 0.007), desmoglein 3 (126 vs. 79, P = 0.004) and desmoglein 1 antibody levels (126 vs. 94, P = 0.004). There was a significant improvement in subjective disease activity scores while on IVIg compared with placebo (mean overall score 11.6 vs. 20.6, P < 0.0001). The results of this study confirm a beneficial effect of IVIg in the management of refractory PV.
- 1 May 2009
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 160 (5) , 1098-1102
An ‘n-of-1’ placebo-controlled crossover trial of intravenous immunoglobulin as adjuvant therapy in refractory pemphigus vulgaris
Pemphigus vulgaris (PV) is an organ-specific autoimmune blistering mucocutaneous disorder that is potentially fatal. High-dose intravenous immunoglobulin (IVIg) is increasingly used in the treatment of autoimmune diseases and it has been reported that it may also be effective in PV. To evaluate prospectively the efficacy of IVIg for PV using an 'n-of-1' placebo-controlled trial. A randomized, placebo-controlled, crossover trial of IVIg was conducted in a single patient with severe PV, comprising two phases of six consecutive months of either IVIg or placebo infusion. Before the commencement of the trial, the patient had received 18 months of IVIg but concerns about the continuing therapeutic efficacy of IVIg led to the double-blind placebo-controlled 'n-of-1' trial of IVIg. Pemphigus autoantibody titres were significantly higher when on placebo compared with IVIg treatment (median 1 : 80 vs. 1 : 20, P = 0.007), desmoglein 3 (126 vs. 79, P = 0.004) and desmoglein 1 antibody levels (126 vs. 94, P = 0.004). There was a significant improvement in subjective disease activity scores while on IVIg compared with placebo (mean overall score 11.6 vs. 20.6, P < 0.0001). The results of this study confirm a beneficial effect of IVIg in the management of refractory PV.
- Open Access
- 1 May 2004
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 97 (5) , 303-308
Antinuclear antibody-negative lupus as a distinct diagnostic entity—does it no longer exist?
Systemic lupus erythematosus (SLE) is a multi-system autoimmune disorder with protean clinical presentations. Historically, Biett reported the first case of lupus erythematosus in 1833, and Kaposi later described the systemic form in 1872,1 but the varied presentation of this illness has made it a challenging diagnosis for clinicians. The difficulties in the diagnosis of SLE were considerably eased by the demonstration of antinuclear antibodies (ANA) as a marker of lupus, initially in the form of LE cells2 and later by indirect immunofluorescence.3 Since then, ANA positivity has become an important diagnostic criterion for the diagnosis of SLE and officially recognised as such by its inclusion in the American College of Rheumatology's criteria for the classification of this disorder.4, 5
- 1 May 2004
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 97 (5) , 303-308
Open AccessAntinuclear antibody-negative lupus as a distinct diagnostic entity—does it no longer exist?
Systemic lupus erythematosus (SLE) is a multi-system autoimmune disorder with protean clinical presentations. Historically, Biett reported the first case of lupus erythematosus in 1833, and Kaposi later described the systemic form in 1872,1 but the varied presentation of this illness has made it a challenging diagnosis for clinicians. The difficulties in the diagnosis of SLE were considerably eased by the demonstration of antinuclear antibodies (ANA) as a marker of lupus, initially in the form of LE cells2 and later by indirect immunofluorescence.3 Since then, ANA positivity has become an important diagnostic criterion for the diagnosis of SLE and officially recognised as such by its inclusion in the American College of Rheumatology's criteria for the classification of this disorder.4, 5